230 related articles for article (PubMed ID: 23634197)
1. Systemic treatment of liver metastases from colorectal cancer.
Stein A; Schmoll HJ
Ther Adv Med Oncol; 2013 May; 5(3):193-203. PubMed ID: 23634197
[TBL] [Abstract][Full Text] [Related]
2. The role of peri-operative treatment in resectable liver metastases of colorectal cancer.
Stein A; Rüssel J; Peinert S; Arnold D
Ther Adv Med Oncol; 2010 Nov; 2(6):389-98. PubMed ID: 21789150
[TBL] [Abstract][Full Text] [Related]
3. Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases.
Pietrantonio F; Di Bartolomeo M; Cotsoglou C; Mennitto A; Berenato R; Morano F; Coppa J; Perrone F; Iacovelli R; Milione M; Alessi A; Vaiani M; Bossi I; Ricchini F; Scotti M; Caporale M; Bajetta E; de Braud F; Mazzaferro V
Clin Colorectal Cancer; 2017 Sep; 16(3):e191-e198. PubMed ID: 27979717
[TBL] [Abstract][Full Text] [Related]
4. Multidisciplinary approach of colorectal liver metastases.
Juez I; Rubio C; Figueras J
Clin Transl Oncol; 2011 Oct; 13(10):721-7. PubMed ID: 21975333
[TBL] [Abstract][Full Text] [Related]
5. Liver resection for colorectal cancer metastases.
Gallinger S; Biagi JJ; Fletcher GG; Nhan C; Ruo L; McLeod RS
Curr Oncol; 2013 Jun; 20(3):e255-65. PubMed ID: 23737695
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy of liver resection after downsizing systemic chemotherapy for initially unresectable liver metastases.
Kawamura J; Yazawa T; Sumida K; Kida Y; Ogawa R; Tani M; Kawasoe J; Yamamoto M; Harada H; Yamamoto H; Zaima M
World J Surg Oncol; 2016 Feb; 14():56. PubMed ID: 26911142
[TBL] [Abstract][Full Text] [Related]
7. Treatment strategies for colorectal carcinoma with synchronous liver metastases: Which way to go?
Ihnát P; Vávra P; Zonča P
World J Gastroenterol; 2015 Jun; 21(22):7014-21. PubMed ID: 26078580
[TBL] [Abstract][Full Text] [Related]
8. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection.
Wong R; Cunningham D; Barbachano Y; Saffery C; Valle J; Hickish T; Mudan S; Brown G; Khan A; Wotherspoon A; Strimpakos AS; Thomas J; Compton S; Chua YJ; Chau I
Ann Oncol; 2011 Sep; 22(9):2042-2048. PubMed ID: 21285134
[TBL] [Abstract][Full Text] [Related]
9. Management of potentially resectable colorectal cancer liver metastases.
Meriggi F; Bertocchi P; Zaniboni A
World J Gastrointest Surg; 2013 May; 5(5):138-45. PubMed ID: 23710291
[TBL] [Abstract][Full Text] [Related]
10. Borderline resectable for colorectal liver metastases: Present status and future perspective.
Kitano Y; Hayashi H; Matsumoto T; Kinoshita S; Sato H; Shiraishi Y; Nakao Y; Kaida T; Imai K; Yamashita YI; Baba H
World J Gastrointest Surg; 2021 Aug; 13(8):756-763. PubMed ID: 34512899
[TBL] [Abstract][Full Text] [Related]
11. Optimal timing of systemic therapy in resectable colorectal liver metastases.
Ihemelandu C; Levine EA; Aklilu M; Yacoub G; Howerton R; Bolemon B; Graham M; Russell G; Shen P
Am Surg; 2013 Apr; 79(4):414-21. PubMed ID: 23574853
[TBL] [Abstract][Full Text] [Related]
12. [HEMIHEPATECTOMY FOR RESECTABLE HEPATIC METASTASIS FROM COLORECTAL CANCER WITH POOR PROGNOSIS].
Patyutko YI; Kotelnikov AG; Mamontov KG; Podluzhny DV; Ponomarenko AA
Vopr Onkol; 2015; 61(3):439-47. PubMed ID: 26242159
[TBL] [Abstract][Full Text] [Related]
13. Current state of surgical treatment of liver metastases from colorectal cancer.
Grundmann RT
World J Gastrointest Surg; 2011 Dec; 3(12):183-96. PubMed ID: 22224173
[TBL] [Abstract][Full Text] [Related]
14. Optimal indication criteria for neoadjuvant chemotherapy in patients with resectable colorectal liver metastases.
Ichida H; Mise Y; Ito H; Ishizawa T; Inoue Y; Takahashi Y; Shinozaki E; Yamaguchi K; Saiura A
World J Surg Oncol; 2019 Jun; 17(1):100. PubMed ID: 31196104
[TBL] [Abstract][Full Text] [Related]
15. The Landmark Series: Randomized Control Trials Examining Perioperative Chemotherapy and Postoperative Adjuvant Chemotherapy for Resectable Colorectal Liver Metastasis.
Kawaguchi Y; Vauthey JN
Ann Surg Oncol; 2020 Oct; 27(11):4263-4270. PubMed ID: 32803551
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Liver Metastases From Colorectal Cancer: Medico-Surgical Strategies.
Essadi I; Sbitti Y; Fetohi M; Slimani KA; Essadi M; Tazi E; Ichou M; Errihani H
Gastroenterology Res; 2011 Jun; 4(3):122-124. PubMed ID: 27942326
[TBL] [Abstract][Full Text] [Related]
17. Liver resection after chemotherapy and tumour downsizing in patients with initially unresectable colorectal cancer liver metastases.
Devaud N; Kanji ZS; Dhani N; Grant RC; Shoushtari H; Serrano PE; Nanji S; Greig PD; McGilvray I; Moulton CA; Wei A; Gallinger S; Cleary SP
HPB (Oxford); 2014 May; 16(5):475-80. PubMed ID: 23927606
[TBL] [Abstract][Full Text] [Related]
18. Treatment strategies to resectable metachronous colorectal liver metastases after adjuvant oxaliplatin-based chemotherapy for primary colorectal cancer.
Julio C; Benoist S; Allard MA; Navarro F; Pessaux P; Sa Cunha A; Brouquet A;
J Surg Oncol; 2022 Aug; 126(2):330-338. PubMed ID: 35397122
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Impact of Tumor Markers (CEA and CA19-9) on Patients with Resectable Colorectal Liver Metastases Stratified by Tumor Number and Size: Potentially Valuable Biologic Markers for Preoperative Treatment.
Kobayashi K; Ono Y; Kitano Y; Oba A; Sato T; Ito H; Mise Y; Shinozaki E; Inoue Y; Yamaguchi K; Saiura A; Takahashi Y
Ann Surg Oncol; 2023 Nov; 30(12):7338-7347. PubMed ID: 37365416
[TBL] [Abstract][Full Text] [Related]
20. Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6).
Rovers KP; Bakkers C; Simkens GAAM; Burger JWA; Nienhuijs SW; Creemers GM; Thijs AMJ; Brandt-Kerkhof ARM; Madsen EVE; Ayez N; de Boer NL; van Meerten E; Tuynman JB; Kusters M; Sluiter NR; Verheul HMW; van der Vliet HJ; Wiezer MJ; Boerma D; Wassenaar ECE; Los M; Hunting CB; Aalbers AGJ; Kok NFM; Kuhlmann KFD; Boot H; Chalabi M; Kruijff S; Been LB; van Ginkel RJ; de Groot DJA; Fehrmann RSN; de Wilt JHW; Bremers AJA; de Reuver PR; Radema SA; Herbschleb KH; van Grevenstein WMU; Witkamp AJ; Koopman M; Haj Mohammad N; van Duyn EB; Mastboom WJB; Mekenkamp LJM; Nederend J; Lahaye MJ; Snaebjornsson P; Verhoef C; van Laarhoven HWM; Zwinderman AH; Bouma JM; Kranenburg O; van 't Erve I; Fijneman RJA; Dijkgraaf MGW; Hemmer PHJ; Punt CJA; Tanis PJ; de Hingh IHJT; ;
BMC Cancer; 2019 Apr; 19(1):390. PubMed ID: 31023318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
